Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07294885
Recruiting Not applicable

Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease

NCT07294885 · tracked via the Priya Life Science China tracker
Sponsor
General Hospital of Shenyang Military Region
Phase
Not applicable
Started
2026-03-20
Last updated
2026-03-25

Condition(s) studied

Alzheimer Disease

Investigational drug(s) / intervention(s)

deep cervical lymphaticovenous anastomosis

deep cervical lymphaticovenous anastomosis: patients will receive deep cervical lymphaticovenous anastomosis

Study summary

Lymphaticovenous anastomosis (LVA) is a microsurgical technique that involves anastomosing fine lymphatic vessels with adjacent veins to reestablish lymphatic drainage pathways. It is used in the treatment of lymphedema-related conditions and is characterized by minimal invasiveness and rapid recovery. Based on findings from animal studies, some physicians in China have attempted deep cervical lymphatic-venous anastomosis to improve intracranial lymphatic drainage in patients with Alzheimer's disease (AD). Most studies, including those from our center, have observed early postoperative improvements in various domains such as mood, memory, executive function, and communication abilities in the majority of patients. However, these symptomatic improvements are not sustained. The reasons for the early improvements remain unclear. Are they due to enhanced lymphatic drainage resulting from the surgery itself, or are they attributable to other factors such as anesthetic effects, vascular release, or modulation of sympathetic nerves? Therefore, it is necessary to conduct a randomized controlled trial with a sham surgery group to clarify the causes of early clinical symptom improvements. Based on this, this project aims to carry out a prospective, single-center, randomized double-blind controlled study to evaluate whether the early symptomatic improvements following deep cervical LVA in AD patients are attributable to the surgical intervention itself or to other aspects of the procedure.

Eligibility

Sex
ALL
Min age
50 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Age 50-80 years (inclusive), regardless of gender. * Meeting the diagnostic criteria for Mild Cognitive Impairment or mild to moderate dementia due to Alzheimer's disease (according to the 2024 AA clinical diagnostic criteria for AD-related dementia). * Disease duration of 6 months or longer, with no clinical improvement after 3 months or more of conservative treatment. * MMSE score: 12-26. * Biomarker confirmation of AD: positive Aβ-PET and tau-PET, or positive cerebrospinal fluid biomarkers. * Having a reliable caregiver (providing companionship for ≥3 hours per day). * Signed written informed consent from the patient or legally authorized representative. Exclusion Criteria: * Contraindications to MRI, ICG angiography, or PET. * Contraindications to surgery or anesthesia, such as coagulation disorders (platelet count \<100×10⁹/L, INR \>1.7). * Comorbid major organ dysfunction, such as reduced left ventricular ejection fraction, severe hepatic or renal insufficiency (AST or ALT \>3 times the upper limit of normal; eGFR \<30 mL/min/1.73m²). * Intracranial structural lesions indicated by MRI, including brain tumors, cerebral infarction, intracranial hemorrhage, aneurysms, arteriovenous malformations, hydrocephalus, etc. * MRI findings suggestive of significant cerebral small vessel disease features: more than one lacunar infarction in the deep white matter and periventricular regions and/or white matter hyperintensity (WMH) with a Fazekas grade \>2, or the presence of ≥4 cerebral microbleeds. * Other causes of dementia, such as hypothyroidism or vitamin B12 deficiency. * Drug/alcohol addiction. * Severe psychiatric illness or suicide risk. * Comorbid medical conditions with a life expectancy of less than 1 year. * Participation in another interventional trial within the past 3 months. * Poor compliance or judged by the investigator as unsuitable for participation. * Patients receiving therapy with Lecanemab or Donanemab. * Other conditions that the researcher deems unsuitable for participation in this study.

Primary outcome measure(s)

  • Changes in Montreal Cognitive Assessment (MoCA) score — 4±1 days
    MoCA ranges from 0 to 30, with higher score meaning better outcome
  • Changes in Mini-mental State Examination (MMSE) score — 4±1 days
    MMSE ranges from 0 to 30, with higher score meaning better outcome
  • Changes in Barthel index (BI) — 4±1 days
    BI ranges from 0 to 100, with higher score meaning better outcome
  • Changes in Clinician's Interview-Based Impression of Change-plus caregiver input (CIBIC-plus) — 4±1 days
    CIBIC-plus ranges from 1 to 7, with higher score meaning worse outcome

Trial sites (1)

FacilityCityRegionStatus
Department of Neurology, General Hospital of Northern Theater Command Shenyang China Recruiting

More General Hospital of Shenyang Military Region trials in China

Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia Recruiting
The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques Recruiting
Head dOwn Position Before Endovascular Treatment for Large veSsel Occlusion (HOPES5) Recruiting
Remote Ischemic Conditioning Plus Stenting for Symptomatic Carotid Artery Stenosis Recruiting
Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours of Onset With Prourokinase Recruiting

Other trials for the same condition

Clinical Evaluation of Acupuncture Treatment on Alzheimer's Disease in APOE e4 Carriers and Non-Carriers Recruiting
Study on Biomarkers for Early Diagnosis of Alzheimer's Disease Recruiting
Study on the Relationship Between Peripheral Blood miRNA and Risk and Severity of Alzheimer's Disease Recruiting
A Study of CM383 in Patients With Alzheimer's Disease Related Mild Cognitive Impairment and Mild Alzheimer's Disease Recruiting
Cognitive Impairment Cohort Study of the Elderly Population in SheMountain Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07294885 on ClinicalTrials.gov ↗ ← All trials in China